BRAF and melanoma: On the basis of the evidence that these oncogenic BRAF mutations are detectable in about 50% of patients (pts) with cutaneous melanoma [4], research was focused on the inhibition of this pathway in order to reverse uncontrolled growth of melanoma cells.